{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:16:33Z","timestamp":1787318193555,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2023CXA017"],"award-info":[{"award-number":["2023CXA017"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J01600"],"award-info":[{"award-number":["2023J01600"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","award":["J200010"],"award-info":[{"award-number":["J200010"]}],"id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejps.2024.106707","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T12:51:42Z","timestamp":1705755102000},"page":"106707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy"],"prefix":"10.1016","volume":"194","author":[{"given":"Yuying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinfang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106707_bib0001","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","article-title":"Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy","volume":"47","author":"Abduljalil","year":"2020","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2024.106707_bib0002","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40262-019-00845-2","article-title":"Therapeutic drug monitoring of antiepileptic drugs in women with epilepsy before, during, and after pregnancy","volume":"59","author":"Arfman","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106707_bib0003","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1111\/epi.13733","article-title":"Placental passage of antiepileptic drugs at delivery and neonatal outcomes","volume":"58","author":"Bank","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2024.106707_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-199400910-00002","article-title":"Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects","volume":"9","author":"Bareggi","year":"1994","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-198510030-00007","article-title":"Plasma concentrations of carbamazepine and carbamazepine 10,11-epoxide during pregnancy and after delivery","volume":"10","author":"Battino","year":"1985","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106707_bib0006","first-page":"46","article-title":"Effect of piperine on the metabolism and pharmacokinetics of carbamazepine in healthy volunteers","volume":"67","author":"Bedada","year":"2017","journal-title":"Drug Res."},{"key":"10.1016\/j.ejps.2024.106707_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0920-1211(95)00012-Y","article-title":"Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy","volume":"21","author":"Bernus","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2024.106707_bib0008","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003088-197803020-00003","article-title":"Clinical pharmacokinetics of carbamazepine","volume":"3","author":"Bertilsson","year":"1978","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106707_bib0009","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-198611030-00001","article-title":"Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update","volume":"11","author":"Bertilsson","year":"1986","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106707_bib0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.seizure.2020.10.018","article-title":"Current role of carbamazepine and oxcarbazepine in the management of epilepsy","volume":"83","author":"Beydoun","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.ejps.2024.106707_bib0011","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.clinbiochem.2015.05.014","article-title":"Routine therapeutic monitoring of the active metabolite of carbamazepine: Is it really necessary?","volume":"48","author":"Burianov\u00e1","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejps.2024.106707_bib0012","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1067\/mcp.2000.111530","article-title":"Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers","volume":"68","author":"Burstein","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106707_bib0013","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.0306-5251.2003.01919.x","article-title":"Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human","volume":"56","author":"Cazali","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0014","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00561065","article-title":"The pharmacokinetics of carbamazepine","volume":"12","author":"Cotter","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0015","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40262-017-0539-z","article-title":"Gestation-specific changes in the anatomy and physiology of healthy pregnant women: An extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy","volume":"56","author":"Dallmann","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106707_bib0016","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/psp4.12300","article-title":"Applied concepts in PBPK modeling: How to extend an open systems pharmacology model to the special population of pregnant women","volume":"7","author":"Dallmann","year":"2018","journal-title":"CPT Pharmacometrics. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00003088-197904010-00005","article-title":"Antiepileptic drugs: metabolism in pregnancy","volume":"4","author":"Dam","year":"1979","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106707_bib0018","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bcp.12815","article-title":"Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models","volume":"81","author":"De Sousa Mendes","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00562659","article-title":"Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses","volume":"8","author":"Eichelbaum","year":"1975","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/01480545.2019.1601736","article-title":"Silymarin as a flavonoid-type P-glycoprotein inhibitor with impact on the pharmacokinetics of carbamazepine, oxcarbazepine and phenytoin in rats","volume":"44","author":"Ferreira","year":"2021","journal-title":"Drug Chem. Toxicol."},{"key":"10.1016\/j.ejps.2024.106707_bib0021","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/pharmaceutics13020270","article-title":"Pharmacokinetics of the CYP3A4 and CYP2B6 inducer carbamazepine and its drug-drug interaction potential: A physiologically based pharmacokinetic modeling approach","volume":"13","author":"Fuhr","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106707_bib0022","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.xphs.2021.02.019","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: carbamazepine","volume":"110","author":"Garc\u00eda","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106707_bib0023","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF01064556","article-title":"Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses","volume":"4","author":"G\u00e9radin","year":"1976","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2024.106707_bib0024","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1528-1157.1990.tb05384.x","article-title":"Absolute bioavailability of carbamazepine after oral administration of a 2% syrup","volume":"31","author":"G\u00e9rardin","year":"1990","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2024.106707_bib0025","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNF.0000000000000172","article-title":"Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach","volume":"39","author":"Greenberg","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0026","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007691-198503000-00005","article-title":"Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies","volume":"7","author":"Hooper","year":"1985","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2024.106707_bib0027","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1124\/dmd.104.001313","article-title":"Evidence of significant contribution from CYP3A5 to hepatic drug metabolism","volume":"32","author":"Huang","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106707_bib0028","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.tjog.2019.10.004","article-title":"Soluble epoxide hydrolase in the human placenta throughout gestation","volume":"58","author":"Hung","year":"2019","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"10.1016\/j.ejps.2024.106707_bib0029","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00007611-200194030-00007","article-title":"Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants","volume":"94","author":"Iqbal","year":"2001","journal-title":"South Med. J."},{"key":"10.1016\/j.ejps.2024.106707_bib0030","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/dmd.112.050245","article-title":"Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?","volume":"41","author":"Isoherranen","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106707_bib0031","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2014.02.011","article-title":"Carbamazepine clearance and seizure stability during pregnancy","volume":"33","author":"Johnson","year":"2014","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ejps.2024.106707_bib0032","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eplepsyres.2016.02.013","article-title":"Concentrations of carbamazepine and carbamazepine-10,11-epoxide in maternal and umbilical cord blood at birth: Influence of co-administration of valproic acid or enzyme-inducing antiepileptic drugs","volume":"122","author":"Kacirova","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2024.106707_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111412","article-title":"Therapeutic monitoring of carbamazepine and its active metabolite during the 1st postnatal month: Influence of drug interactions","volume":"137","author":"Kacirova","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2024.106707_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113176","article-title":"Carbamazepine and carbamazepine-epoxide concentrations in mothers, colostrum, and breastfed newborns: Comparison with concentrations determined during delivery and in the mature milk period","volume":"151","author":"Kacirova","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2024.106707_bib0035","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.655320","article-title":"Pregnancy-related hormones increase UGT1A1-mediated labetalol metabolism in human hepatocytes","volume":"12","author":"Khatri","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0037","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1208\/s12248-017-0149-6","article-title":"Investigating oral absorption of carbamazepine in pediatric populations","volume":"19","author":"Kohlmann","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2024.106707_bib0038","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/psp4.12134","article-title":"Applied concepts in PBPK modeling: How to build a PBPK\/PD model","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT. Pharmacometrics. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0039","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-2008-1041385","article-title":"Pharmacokinetics of antiepileptic drugs during pregnancy","volume":"8","author":"Leppik","year":"1988","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.ejps.2024.106707_bib0040","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cpt1975176657","article-title":"Pharmacokinetics of carbamazepine in normal man","volume":"17","author":"Levy","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106707_bib0041","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2217\/pgs.15.94","article-title":"Association between PK\/PD-involved gene polymorphisms and carbamazepine-individualized therapy","volume":"16","author":"Ma","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejps.2024.106707_bib0042","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2125.1984.tb02496.x","article-title":"Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein","volume":"18","author":"MacKichan","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0043","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.2011.251","article-title":"Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex","volume":"91","author":"Marino","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106707_bib0044","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2133.1988.tb03236.x","article-title":"Effect of isotretinoin on carbamazepine pharmacokinetics","volume":"119","author":"Marsden","year":"1988","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejps.2024.106707_bib0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/00912700122010005","article-title":"The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation","volume":"41","author":"McLean","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0046","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40262-020-00861-7","article-title":"Integration of placental transfer in a fetal-maternal physiologically based pharmacokinetic model to characterize acetaminophen exposure and metabolic clearance in the fetus","volume":"59","author":"Mian","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106707_bib0047","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.arcmed.2003.09.016","article-title":"Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment","volume":"35","author":"Moreno","year":"2004","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.ejps.2024.106707_bib0048","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2165\/00003088-198207060-00003","article-title":"Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics","volume":"7","author":"Nau","year":"1982","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106707_bib0049","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"4","author":"Nevitt","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejps.2024.106707_bib0050","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1210\/jc.2011-1437","article-title":"Maternal smoking and fetal sex significantly affect metabolic enzyme expression in the human fetal liver","volume":"96","author":"O'Shaughnessy","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2024.106707_bib0051","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/cap.1998.8.161","article-title":"A review of developmental aspects of cytochrome P450","volume":"8","author":"Oesterheld","year":"1998","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0052","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2125.2001.01359.x","article-title":"Carbamazepine is not a substrate for P-glycoprotein","volume":"51","author":"Owen","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0053","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2024.106707_bib0054","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/dmd.30.11.1170","article-title":"Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites","volume":"30","author":"Pearce","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106707_bib0055","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0074-7742(08)00013-5","article-title":"Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics","volume":"83","author":"Pennell","year":"2008","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.ejps.2024.106707_bib0056","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamaneurol.2021.5487","article-title":"Antiseizure medication concentrations during pregnancy: results from the maternal outcomes and neurodevelopmental effects of antiepileptic drugs (MONEAD) study","volume":"79","author":"Pennell","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejps.2024.106707_bib0057","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1212\/01.wnl.0000289511.20864.2a","article-title":"Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency","volume":"70","author":"Pennell","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ejps.2024.106707_bib0058","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1528-1157.1995.tb00991.x","article-title":"Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood","volume":"36","author":"Pienim\u00e4ki","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2024.106707_bib0059","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1528-1157.1997.tb01122.x","article-title":"Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta","volume":"38","author":"Pienim\u00e4ki","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2024.106707_bib0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1528-1157.1990.tb05385.x","article-title":"Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study","volume":"31","author":"Pisani","year":"1990","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2024.106707_bib0061","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0920-1211(94)90068-X","article-title":"Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy","volume":"19","author":"Pisani","year":"1994","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2024.106707_bib0062","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejps.2024.106707_bib0063","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1600-0773.1977.tb02157.x","article-title":"The pharmacokinetics of carbamazepine in plasma and saliva of man","volume":"41","author":"Pynn\u00f6nen","year":"1977","journal-title":"Acta Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2024.106707_bib0064","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0773.1977.tb02145.x","article-title":"Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk","volume":"41","author":"Pynn\u00f6nen","year":"1977","journal-title":"Acta Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2024.106707_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.06.008","article-title":"Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients","volume":"62","author":"Ragueneau-Majlessi","year":"2004","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2024.106707_bib0066","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00567129","article-title":"Disposition of placentally transferred carbamazepine (Tegretol) in the newborn","volume":"8","author":"Rane","year":"1975","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0067","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00561556","article-title":"Distribution and elimination kinetics of carbamazepine in man","volume":"8","author":"Rawlins","year":"1975","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106707_bib0068","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yebeh.2013.06.026","article-title":"Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy","volume":"29","author":"Reisinger","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ejps.2024.106707_bib0069","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007691-199412000-00001","article-title":"Carbamazepine and its epoxide: an open study of efficacy and side effects after carbamazepine dose increment in refractory partial epilepsy","volume":"16","author":"Semah","year":"1994","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2024.106707_bib0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00007691-198804000-00003","article-title":"Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine","volume":"10","author":"Spina","year":"1988","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2024.106707_bib0071","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1124\/jpet.104.073114","article-title":"N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7","volume":"311","author":"Staines","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2024.106707_bib0072","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/js980203+","article-title":"Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR)","volume":"87","author":"Stevens","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106707_bib0073","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0920-1211(92)90070-A","article-title":"Protein binding of four antiepileptic drugs in maternal and umbilical cord serum","volume":"13","author":"Takeda","year":"1992","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2024.106707_bib0074","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/epi.13012","article-title":"Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy","volume":"56","author":"Tolbert","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2024.106707_bib0075","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejps.2024.106707_bib0076","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1528-1157.1994.tb02922.x","article-title":"Disposition of carbamazepine and phenytoin in pregnancy","volume":"35","author":"Tomson","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2024.106707_bib0077","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/clpt.1983.8","article-title":"Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide","volume":"33","author":"Tomson","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106707_bib0078","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","article-title":"Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes","volume":"15","author":"Veroniki","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.ejps.2024.106707_bib0079","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0920-1211(90)90042-T","article-title":"Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding","volume":"5","author":"Yerby","year":"1990","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2024.106707_bib0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007691-198507030-00005","article-title":"Carbamazepine protein binding and disposition in pregnancy","volume":"7","author":"Yerby","year":"1985","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2024.106707_bib0081","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1124\/dmd.116.073957","article-title":"Development of a novel maternal-fetal physiologically based pharmacokinetic model II: Verification of the model for passive placental permeability drugs","volume":"45","author":"Zhang","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106707_bib0082","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/s12248-010-9250-9","article-title":"Utility of physiologically based absorption modeling in implementing Quality by Design in drug development","volume":"13","author":"Zhang-Lionberger","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2024.106707_bib0083","article-title":"Physiologically based pharmacokinetic modeling in pregnant women suggests minor decrease in maternal exposure to olanzapine","volume":"12","author":"Zheng","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:09:40Z","timestamp":1760530180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":83,"alternative-id":["S0928098724000186"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106707","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106707"}}